Article Cited by others

INVITED REVIEW

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance

Edlind Merritt P, Hsieh Andrew C

Year : 2014| Volume: 16| Issue : 3 | Page no: 378-386

   This article has been cited by
 
1 MiR-93 functions as a tumor promoter in prostate cancer by targeting disabled homolog 2 (DAB2) and an antitumor polysaccharide from green tea (Camellia sinensis) on their expression
Ke Yang,Yuan-Wei Li,Zhi-Yong Gao,Wei Xiao,Tie-Qiu Li,Wei Song,Jue Zheng,Hao Chen,Gui-Heng Chen,Hao-Yu Zou
International Journal of Biological Macromolecules. 2018;
[Pubmed]  [Google Scholar] [DOI]
2 NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer
Zhixiong Chen,Qilong Jiang,Pingyu Zhu,Yanlin Chen,Xuemei Xie,Zhongbo Du,Li Jiang,Wei Tang
The Prostate. 2018;
[Pubmed]  [Google Scholar] [DOI]
3 Phenethyl isothiocyanate in combination with dibenzoylmethane inhibits the androgen-independent growth of prostate cancer cells
Huarong Huang,Yan He,Lanyue Zhang,Hongping Xiang,Dongli Li,Wenfeng Liu,Xue-Tao Xu,Susan Goodin,Kun Zhang,Xi Zheng
Food & Function. 2018;
[Pubmed]  [Google Scholar] [DOI]
4 Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
Brandon Bumbaca,Wei Li
Acta Pharmaceutica Sinica B. 2018;
[Pubmed]  [Google Scholar] [DOI]
5 T-cell lymphomas associated gene expression signature: Bioinformatics analysis based on gene expression Omnibus
Lei-lei Zhou,Xiao-yue Xu,Jie Ni,Xia Zhao,Jian-wei Zhou,Ji-feng Feng
European Journal of Haematology. 2018;
[Pubmed]  [Google Scholar] [DOI]
6 A Systems-Level Analysis of Mechanisms of Platycodon grandiflorum Based on A Network Pharmacological Approach
Musun Park,Sa-Yoon Park,Hae-Jeung Lee,Chang-Eop Kim
Molecules. 2018; 23(11): 2841
[Pubmed]  [Google Scholar] [DOI]
7 Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer
H. Alexander Ebhardt,Alex Root,Yansheng Liu,Nicholas Paul Gauthier,Chris Sander,Ruedi Aebersold
npj Systems Biology and Applications. 2018; 4(1)
[Pubmed]  [Google Scholar] [DOI]
8 Influence and mechanism of Angiotensin 1-7 on biological properties of normal prostate epithelial cells
Kamila Dominska,Piotr Okla,Karolina Kowalska,Dominika Ewa Habrowska-Górczynska,Kinga Anna Urbanek,Tomasz Ochedalski,Agnieszka Wanda Piastowska-Ciesielska
Biochemical and Biophysical Research Communications. 2018; 502(1): 152
[Pubmed]  [Google Scholar] [DOI]
9 Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats
Bianca Facchim Gonçalves,Silvana Gisele Pegorin de Campos,Wagner José Fávaro,Joyce Zalotti Brandt,Cristiane Figueiredo Pinho,Luis Antônio Justulin,Sebastião Roberto Taboga,Wellerson Rodrigo Scarano
Hormones and Cancer. 2018;
[Pubmed]  [Google Scholar] [DOI]
10 A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers
Philipp Y Maximov,Balkees Abderrahman,Ramona F Curpan,Yousef M Hawsawi,Ping Fan,V Craig Jordan
Endocrine-Related Cancer. 2018; 25(2): R83
[Pubmed]  [Google Scholar] [DOI]
11 A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer
Nisha R. Dahiya,Balaji Chandrasekaran,Venkatesh Kolluru,Murali Ankem,Chendil Damodaran,Manicka V. Vadhanam
Molecular Carcinogenesis. 2018;
[Pubmed]  [Google Scholar] [DOI]
12 Androgen receptor: what we know and what we expect in castration-resistant prostate cancer
Zhonglin Cai,Weijie Chen,Jianzhong Zhang,Hongjun Li
International Urology and Nephrology. 2018;
[Pubmed]  [Google Scholar] [DOI]
13 Targeting AR-Beclin 1 Complex-Modulated Growth Factor Signaling Increases the Antiandrogen-Enzalutamide Sensitivity to Better Suppress the Castration-Resistant Prostate Cancer Growth
Meng Zhang,Yin Sun,Jialin Meng,Li Zhang,Chaozhao Liang,Chawnshang Chang
Cancer Letters. 2018;
[Pubmed]  [Google Scholar] [DOI]
14 PI3K pathway in prostate cancer: All resistant roads lead to PI3K
Soonbum Park,Young Sik Kim,Davis Yeon Kim,Insuk So,Ju-Hong Jeon
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2018; 1870(2): 198
[Pubmed]  [Google Scholar] [DOI]
15 Clinical implications of PTEN loss in prostate cancer
Tamara Jamaspishvili,David M. Berman,Ashley E. Ross,Howard I. Scher,Angelo M. De Marzo,Jeremy A. Squire,Tamara L. Lotan
Nature Reviews Urology. 2018;
[Pubmed]  [Google Scholar] [DOI]
16 Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes
Matthew Utter,Sohag Chakraborty,Limor Goren,Lucas Feuser,Yuan-Shan Zhu,David A. Foster
Cancer Letters. 2018;
[Pubmed]  [Google Scholar] [DOI]
17 A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
Laura Graham,Kalyan Banda,Alba Torres,Brett S. Carver,Yu Chen,Katie Pisano,Greg Shelkey,Tracy Curley,Howard I. Scher,Tamara L. Lotan,Andrew C. Hsieh,Dana E. Rathkopf
Investigational New Drugs. 2018;
[Pubmed]  [Google Scholar] [DOI]
18 Mechanisms of Therapeutic Resistance in Prostate Cancer
Mary Nakazawa,Channing Paller,Natasha Kyprianou
Current Oncology Reports. 2017; 19(2)
[Pubmed]  [Google Scholar] [DOI]
19 SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway
Benjiang Qian,Yi Yao,Changming Liu,Jiabing Zhang,Huihong Chen,Huizhang Li
International Journal of Oncology. 2017; 50(5): 1601
[Pubmed]  [Google Scholar] [DOI]
20 mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia
Fabio Di Domenico,Antonella Tramutola,Cesira Foppoli,Elizabeth Head,Marzia Perluigi,D. Allan Butterfield
Free Radical Biology and Medicine. 2017;
[Pubmed]  [Google Scholar] [DOI]
21 Acne vulgaris: the metabolic syndrome of the pilo-sebaceous follicle
Bodo C. Melnik
Clinics in Dermatology. 2017;
[Pubmed]  [Google Scholar] [DOI]
22 Investigational serine/threonine kinase inhibitors against prostate cancer metastases
Claudio Festuccia
Expert Opinion on Investigational Drugs. 2017; 26(1): 25
[Pubmed]  [Google Scholar] [DOI]
23 IL-8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NF-?B pathway in prostate cancer
Yidi Guo,Ying Zang,Lianzheng Lv,Feng Cai,Tingting Qian,Guoying Zhang,Quancheng Feng
Molecular Medicine Reports. 2017; 16(6): 9035
[Pubmed]  [Google Scholar] [DOI]
24 Synergistic effects of phenylhexyl isothiocyanate and LY294002 on the PI3K/Akt signaling pathway in HL-60 cells
Huicong Yang,Yiqun Huang,Yong Zou,Xudong Ma
Oncology Letters. 2017; 14(3): 3043
[Pubmed]  [Google Scholar] [DOI]
25 PTEN loss and activation of K-RAS and ß-catenin cooperate to accelerate prostate tumourigenesis
Matthew T Jefferies,Adam C Cox,Boris Y Shorning,Valerie Meniel,David Griffiths,Howard G Kynaston,Matthew J Smalley,Alan R Clarke
The Journal of Pathology. 2017; 243(4): 442
[Pubmed]  [Google Scholar] [DOI]
26 Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways
Ewelina Górowska-Wójtowicz,Anna Hejmej,Alicja Kaminska,Laura Pardyak,Malgorzata Kotula-Balak,Joanna Dulinska-Litewka,Piotr Laidler,Barbara Bilinska
Toxicology in Vitro. 2017;
[Pubmed]  [Google Scholar] [DOI]
27 miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A
Xiaodi Qiu,Ying Dou
Biomedicine & Pharmacotherapy. 2017; 88: 430
[Pubmed]  [Google Scholar] [DOI]
28 MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K/AKT/mTOR pathway in prostate cancer
Song Xu,Jingping Ge,Zhengyu Zhang,Wenquan Zhou
Biomedicine & Pharmacotherapy. 2017; 96: 634
[Pubmed]  [Google Scholar] [DOI]
29 The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer
L S DæAbronzo,S Bose,M E Crapuchettes,R E Beggs,R L Vinall,C G Tepper,S Siddiqui,M Mudryj,F U Melgoza,B P Durbin-Johnson,R W deVere White,P M Ghosh
Oncogene. 2017;
[Pubmed]  [Google Scholar] [DOI]
30 Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer
Cuicui Zhu,Qingyi Zhu,Zhaomeng Wu,Yingying Yin,Dan Kang,Shan Lu,Ping Liu
Journal of Cellular Physiology. 2017;
[Pubmed]  [Google Scholar] [DOI]
31 Protein kinase B
Bhumika Wadhwa,Ubaid Makhdoomi,Ram Vishwakarma,Fayaz Malik
Anti-Cancer Drugs. 2017; 28(6): 569
[Pubmed]  [Google Scholar] [DOI]
32 MiR-1271 Inhibits Cell Growth in Prostate Cancer by Targeting ERG
Miao Wang,Wei Gao,Dehong Lu,Lianghong Teng
Pathology & Oncology Research. 2017;
[Pubmed]  [Google Scholar] [DOI]
33 AR Signaling and the PI3K Pathway in Prostate Cancer
Megan Crumbaker,Leila Khoja,Anthony Joshua
Cancers. 2017; 9(4): 34
[Pubmed]  [Google Scholar] [DOI]
34 Effects of Brassicaceae Isothiocyanates on Prostate Cancer
Silvia Novío,María Cartea,Pilar Soengas,Manuel Freire-Garabal,María Núñez-Iglesias
Molecules. 2016; 21(5): 626
[Pubmed]  [Google Scholar] [DOI]
35 The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells
C Morell,A Bort,D Vara,A Ramos-Torres,N Rodríguez-Henche,I Díaz-Laviada
Prostate Cancer and Prostatic Diseases. 2016;
[Pubmed]  [Google Scholar] [DOI]
36 Nimbolide, a neem limonoid inhibits Phosphatidyl Inositol-3 Kinase to activate Glycogen Synthase Kinase-3ß in a hamster model of oral oncogenesis
Josephraj Sophia,Kranthi Kiran Kishore T.,Jaganathan Kowshik,Rajakishore Mishra,Siddavaram Nagini
Scientific Reports. 2016; 6: 22192
[Pubmed]  [Google Scholar] [DOI]
37 Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors
Yang Liu,Yanzhen Yin,Jingya Zhang,Krystle Nomie,Liang Zhang,Dezhi Yang,Michael L. Wang,Guisen Zhao
Archiv der Pharmazie. 2016; : n/a
[Pubmed]  [Google Scholar] [DOI]
38 mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Cara M. Statz,Sara E. Patterson,Susan M. Mockus
Targeted Oncology. 2016;
[Pubmed]  [Google Scholar] [DOI]
39 Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer
M. Pistelli,Z. Ballatore,A. Santinelli,T. Biscotti,F. Piva,G. Occhipinti,A. Della Mora,A. Pagliacci,N. Battelli,L. Bastianelli,M. De lisa,R. Bracci,E. Maccaroni,R. Berardi,S. Cascinu
Oncology Reports. 2016; 36(2): 755
[Pubmed]  [Google Scholar] [DOI]
40 Determination of MLN0128, an investigational antineoplastic agent, in human plasma by LC-MS/MS
Sandeep R. Kunati,Yan Xu
Biomedical Chromatography. 2016;
[Pubmed]  [Google Scholar] [DOI]
41 Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression
Xuechao Wan,Wenhua Huang,Shu Yang,Yalong Zhang,Pu Zhang,Zhe Kong,Tao Li,Hai Wu,Fengxiang Jing,Yao Li
The International Journal of Biochemistry & Cell Biology. 2016; 79: 249
[Pubmed]  [Google Scholar] [DOI]
42 Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
Patricia Mucci LoRusso
Journal of Clinical Oncology. 2016; 34(31): 3803
[Pubmed]  [Google Scholar] [DOI]
43 Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro
Jasmina Makarevic,Igor Tsaur,Eva Juengel,Hendrik Borgmann,Karen Nelson,Christian Thomas,Georg Bartsch,Axel Haferkamp,Roman A. Blaheta
Life Sciences. 2016; 147: 137
[Pubmed]  [Google Scholar] [DOI]
44 Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
Pier-Luc Clermont,Francesco Crea,Yan Ting Chiang,Dong Lin,Amy Zhang,James Z. L. Wang,Abhijit Parolia,Rebecca Wu,Hui Xue,Yuwei Wang,Jiarui Ding,Kelsie L. Thu,Wan L. Lam,Sohrab P. Shah,Colin C. Collins,Yuzhuo Wang,Cheryl D. Helgason
Clinical Epigenetics. 2016; 8(1)
[Pubmed]  [Google Scholar] [DOI]
45 Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients
S. Sideris,F. Aoun,C. N. Martinez,S. Latifyan,A. Awada,G. Costante,T. Gil
Journal of Endocrinological Investigation. 2016;
[Pubmed]  [Google Scholar] [DOI]
46 HOXA1 enhances the cell proliferation, invasion and metastasis of prostate cancer cells
Haitao Wang,Guanzhong Liu,Dan Shen,Huamao Ye,Jinming Huang,Li Jiao,Yinghao Sun
Oncology Reports. 2015;
[Pubmed]  [Google Scholar] [DOI]
47 Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo
Shang-jun Jiang,Shuo Wang
Tumor Biology. 2015; 36(10): 8177
[Pubmed]  [Google Scholar] [DOI]
48 Milk—A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent Translation
Bodo Melnik
International Journal of Molecular Sciences. 2015; 16(8): 17048
[Pubmed]  [Google Scholar] [DOI]
49 Derivatives containing both coumarin and benzimidazole potently induce caspase-dependent apoptosis of cancer cells through inhibition of PI3K-AKT-mTOR signaling
Haitao Liu,Yubin Wang,Ashok Sharma,Rui Mao,Na Jiang,Boying Dun,Jin-Xiong She
Anti-Cancer Drugs. 2015; : 1
[Pubmed]  [Google Scholar] [DOI]
50 Novel Cancer Chemotherapy Hits by Molecular Topology: Dual Akt and Beta-Catenin Inhibitors
Riccardo Zanni,Maria Galvez-Llompart,Cecilia Morell,Nieves Rodríguez-Henche,Inés Díaz-Laviada,Maria Carmen Recio-Iglesias,Ramon Garcia-Domenech,Jorge Galvez,Yuan-Soon Ho
PLOS ONE. 2015; 10(4): e0124244
[Pubmed]  [Google Scholar] [DOI]
51 An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
Jianqing Lin,Aileen Deng,Jean Hoffman-Censits,Geoffrey Gibney,Terry Hyslop,Brooke Miller,Deborah Kilpatrick,Serge Jabbour,William Kevin Kelly
Cancer Treatment Communications. 2015; 4: 192
[Pubmed]  [Google Scholar] [DOI]
52 Persistent androgen receptor addiction in castration-resistant prostate cancer
Michael T. Schweizer,Evan Y. Yu
Journal of Hematology & Oncology. 2015; 8(1)
[Pubmed]  [Google Scholar] [DOI]
53 Transcription factor and microRNA-regulated network motifs for cancer and signal transduction networks
Wen-Tsong Hsieh,Ke-Rung Tzeng,Jin-Shuei Ciou,Jeffrey JP Tsai,Nilubon Kurubanjerdjit,Chien-Hung Huang,Ka-Lok Ng
BMC Systems Biology. 2015; 9(Suppl 1): S5
[Pubmed]  [Google Scholar] [DOI]
54 PI3K/Akt signaling in osteosarcoma
Jian Zhang,Xiao-Hua Yu,Yi-Guo Yan,Cheng Wang,Wen-Jun Wang
Clinica Chimica Acta. 2015; 444: 182
[Pubmed]  [Google Scholar] [DOI]
55 VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo
Zheren Shao,Qi Bao,Fangzhen Jiang,Huan Qian,Quan Fang,Xueqing Hu,Cong Cao
PLOS ONE. 2015; 10(7): e0132655
[Pubmed]  [Google Scholar] [DOI]
56 Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism
Jing-Wen Shih,Ling-Yu Wang,Chiu-Lien Hung,Hsing-Jien Kung,Chia-Ling Hsieh
International Journal of Molecular Sciences. 2015; 16(12): 28943
[Pubmed]  [Google Scholar] [DOI]
57 Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors
A. C. Hsieh,H. G. Nguyen,L. Wen,M. P. Edlind,P. R. Carroll,W. Kim,D. Ruggero
Science Signaling. 2015; 8(403): ra116
[Pubmed]  [Google Scholar] [DOI]
58 The HDL receptor SR-BI is associated with human prostate cancer progression and plays a possible role in establishing androgen independence
David Schörghofer,Katharina Kinslechner,Andrea Preitschopf,Birgit Schütz,Clemens Röhrl,Markus Hengstschläger,Herbert Stangl,Mario Mikula
Reproductive Biology and Endocrinology. 2015; 13(1)
[Pubmed]  [Google Scholar] [DOI]
59 PIP5K1  inhibition as a therapeutic strategy for prostate cancer
J. M. Drake,J. Huang
Proceedings of the National Academy of Sciences. 2014; 111(35): 12578
[Pubmed]  [Google Scholar] [DOI]

 

Read this article